Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rubitecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 3/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rubitecan SCHEMBL8640 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29379605 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL29383355 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL6426025 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL15539941 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28223445 | 1.00 | ABCC4 (1.00) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27953003 | 0.98 | ABCC4 (0.95) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL28308474 | 0.96 | ABCC4 (0.93) | ABCC4HTTABCC3ACHEPTGS1 | |
| Rubitecan SCHEMBL27598505 | 0.94 | ABCC3 (0.89) | ABCC4HTTABCC3ACHEPTGS1 | |
| SCHEMBL25932527 | 0.92 | ABCC4 (0.85) | ABCC4HTTABCC3ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238724-A9 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | Oxalys Pharmaceuticals (CA) | 2017-12-06 | — | — | EP | disclosed |
| EP-3238724-A2 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | Oxalys Pharmaceuticals (CA) | 2017-11-01 | — | — | EP | disclosed |
| US-9295682-B2 | Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments | NUNES ISEU DA SILVA (BR) | 2016-03-29 | — | — | US | disclosed |
| US-20150148369-A1 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | OXALYS PHARMACEUTICALS (CA) | 2015-05-28 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| EP-2514483-A1 | ADJUVANT IMMUNOTHERAPY FOR THE PREVENTIVE, CURATIVE OR PALLIATIVE TREATMENT OF CHRONIC SYSTEMIC DISEASES SUCH AS CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH THESE DISEASES, SUCH AS CACHEXIA, AND REMEDYING ADVERSE EFFECTS OF DRUGS AND TREATMENTS, SUCH AS IMMUNODEPRESSION, NEUTROPENIA AND LYMPHOCYTOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A SPECIALLY SELECTED BIOLOGICAL RESPONSE MODIFIER AND OTHER ANTINEOPLASTIC COMPOUNDS AND/OR OTHER TREATMENTS | Nunes, Iseu Da Silva (BR) | 2012-10-24 | — | — | EP | disclosed |
| US-20120251441-A1 | ADJUVANT IMMUNOTHERAPY FOR THE PREVENTIVE, CURATIVE OR PALLIATIVE TREATMENT OF CHRONIC SYSTEMIC DISEASES SUCH AS CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH DISEASES LIKE CACHEXIA AND CORRECTION OF ADVERSE EFFECTS OF DRUGS SUCH AS IMMUNOSUPPRESSION, NEUTROPENIA AND LYMPHOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A BIOLOGICAL RESPONSE MODIFIER SPECIALLY SELECTED AND OTHER SUBSTANCES WITH ANTINEOPLASTIC ACTION AND/OR OTHER TREATMENTS | NUNES ISEU DA SILVA (BR) | 2012-10-04 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148369-A1 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | SNCA, TOP2A, TOP2B | TOP1 4/4885ABCC4 3120/4885HTT 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.